House and Senate Democrats at the highest levels are now engaged in a fierce debate about what exactly to demand in their ...

Jefferies research analyst John Aiken explains why he wouldn't be surprised to see a 20 per cent decline in the TSX as he ...

NY, joins Morning Joe to discuss the midair crash near Reagan airport between an Army helicopter and passenger plane. Leader ...

President Donald Trump is expected to rally House Republicans Monday at their annual policy retreat as they look to make progress on tax cuts, border security and other ...

But asked Thursday if Democrats could support a debt ceiling hike attached to California wildfire aid, House Minority Leader Hakeem Jeffries (D-N.Y.) said: “It’s a nonstarter.” Some GOP members are ...

WASHINGTON, DC – Congressman Ami Bera (D-CA) has been reappointed to the House Permanent Select Committee on Intelligence for the 119th Congress by Democratic Leader Hakeem Jeffries.

Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the ...

Hakeem Jeffries, a parent of two, made his fatherhood status congressionally official Wednesday by joining the Dads Caucus. The minority leader’s move signals how top Democrats plan to respond ...

The college football season has wrapped up with Ohio State being crowned national champions after defeating Notre Dame in a title game that seemed like it would be a blowout before getting tense late.

Analysts offered varied opinions; Jefferies maintained an 'Underperform' rating, while Nuvama suggested a 'Hold' rating due to lower demand in consumer appliances and revised estimates for FY25-27.

Costfoto / NurPhoto via Getty Images Apple shares fell Tuesday after Jefferies downgraded the stock to an “underperform” from “hold” on Monday. Jefferies noted that flagging iPhone sales ...

Shares of Newgen Software Technologies fell 16 percent after brokerage firm Jefferies downgraded the stock to 'Underperform' from its earlier rating of 'Buy' following the company's December ...